Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Nectero EAST System klinisk undersøgelse (stAAAble)

23. september 2026 opdateret af: Nectero Medical, Inc.

Randomiseret kontrolleret klinisk forsøg (RCT) af Nectero EAST-systemet for små til mellemstore abdominale aortaaneurismer (AAA) StaBiLisering: Evaluering af effektivitet.

The purpose of this randomized clinical trial is to treat patients with small to mid-sized abdominal aortic aneurysms (AAA), maximum diameter of 3.5 cm to 5.0 cm, using a locally delivered, single-dose endovascular treatment. The main question the study aims to answer is to demonstrate efficacy of the product for stabilization of these small to mid-sized AAA.The study will compare the treatment group to the typical standard of care for these patients, surveillance. All subjects will be followed at designated intervals at 30/60 days, 6, 12, 18 and 24 months with continued follow-up annually for up to 5 years.

Studieoversigt

Status

Rekruttering

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

400

Fase

  • Fase 2
  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • New South Wales
      • Randwick, New South Wales, Australien, 2031
        • Rekruttering
        • Prince of Wales Private Hospital- POW Vascular Institute
        • Ledende efterforsker:
          • Ramon Varcoe
        • Kontakt:
    • Arizona
      • Scottsdale, Arizona, Forenede Stater, 85258
        • Rekruttering
        • Honor Health Scottsdale Shea Medical Center
        • Ledende efterforsker:
          • Hasan Aldailami, MD
        • Kontakt:
          • HonorHealth Cardiovascular Research
          • Telefonnummer: 480-323-1046
    • Colorado
      • Aurora, Colorado, Forenede Stater, 80045
        • Aktiv, ikke rekrutterende
        • University of Colorado
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20010
        • Rekruttering
        • Medstar Washington Hospital Center
        • Ledende efterforsker:
          • Steven Abramowitz, MD
        • Kontakt:
        • Kontakt:
    • Florida
    • Georgia
      • Augusta, Georgia, Forenede Stater, 30912
        • Rekruttering
        • Medical College of Georgia
        • Ledende efterforsker:
          • William Jordan, MD
        • Kontakt:
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
        • Rekruttering
        • University of Chicago
        • Kontakt:
        • Ledende efterforsker:
          • Ross Milner, MD
      • Elk Grove, Illinois, Forenede Stater, 60007
        • Ikke rekrutterer endnu
        • Ascension Alexian Brothers
        • Ledende efterforsker:
          • Jack Chamberlin, MD
    • Maine
      • Scarborough, Maine, Forenede Stater, 04074
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • Massachusetts General Hospital
        • Ledende efterforsker:
          • Nikolaos Zacharias, MD
        • Kontakt:
      • Boston, Massachusetts, Forenede Stater, 02215
      • Worcester, Massachusetts, Forenede Stater, 01655
        • Rekruttering
        • University of Massachusetts
        • Kontakt:
        • Ledende efterforsker:
          • Andres Schanzer, MD
    • Michigan
      • Royal Oak, Michigan, Forenede Stater, 48073
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Rekruttering
        • Washington University School of Medicine
        • Ledende efterforsker:
          • Luis Sanchez, MD
        • Kontakt:
    • Nebraska
      • Omaha, Nebraska, Forenede Stater, 68198
        • Rekruttering
        • University of Nebraska Medical Center
        • Ledende efterforsker:
          • Jonathan Thompson, MD
        • Kontakt:
    • New Hampshire
      • Lebanon, New Hampshire, Forenede Stater, 03766
        • Rekruttering
        • Dartmouth Hitchcock Medical Center
        • Ledende efterforsker:
          • Rebecca Scully, MD
        • Kontakt:
    • New York
      • Rochester, New York, Forenede Stater, 14642
      • Stony Brook, New York, Forenede Stater, 11794
    • North Carolina
      • Durham, North Carolina, Forenede Stater, 27710
        • Rekruttering
        • Duke University Medical Center
        • Ledende efterforsker:
          • Chandler Long, MD
        • Kontakt:
    • Ohio
      • Cincinnati, Ohio, Forenede Stater, 45219
      • Cleveland, Ohio, Forenede Stater, 44106
        • Rekruttering
        • University Hospitals Cleveland
        • Ledende efterforsker:
          • Jae Cho, MD
        • Kontakt:
      • Cleveland, Ohio, Forenede Stater, 44195
        • Rekruttering
        • Cleveland Clinic
        • Ledende efterforsker:
          • Francis Caputo, MD
        • Kontakt:
      • Columbus, Ohio, Forenede Stater, 43210
        • Rekruttering
        • The Ohio State University Wexner Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Kristine Orion, MD
      • Columbus, Ohio, Forenede Stater, 43214
        • Rekruttering
        • Ohio Health Riverside
        • Ledende efterforsker:
          • Joseph Campbell, MD
        • Kontakt:
    • Oklahoma
      • Tulsa, Oklahoma, Forenede Stater, 74104
        • Rekruttering
        • Oklahoma Heart Institute
        • Ledende efterforsker:
          • Julia Chen, MD
        • Kontakt:
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239
        • Rekruttering
        • Portland VA Medical Center
        • Ledende efterforsker:
          • Matthew Koopmann, MD
        • Kontakt:
    • Pennsylvania
      • Bethlehem, Pennsylvania, Forenede Stater, 18015
        • Rekruttering
        • St. Luke's University Health Network
        • Ledende efterforsker:
          • Sharvil Sheth, MD
        • Kontakt:
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • Rekruttering
        • Hospital of the University of Pennsylvania
        • Kontakt:
        • Ledende efterforsker:
          • Grace Wang, MD
      • Philadelphia, Pennsylvania, Forenede Stater, 19107
        • Rekruttering
        • Jefferson Clinical Research Institute
        • Kontakt:
        • Ledende efterforsker:
          • Michael Nooromid, MD
      • Pittsburgh, Pennsylvania, Forenede Stater, 15219
        • Rekruttering
        • University of Pittsburgh Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Raymond Eid, MD
    • South Carolina
    • South Dakota
      • Sioux Falls, South Dakota, Forenede Stater, 57108
        • Rekruttering
        • North Central Heart - A Division of Avera Heart Hospital
        • Ledende efterforsker:
          • Michael Bacharach, MD
        • Kontakt:
    • Tennessee
      • Nashville, Tennessee, Forenede Stater, 37232
      • Nashville, Tennessee, Forenede Stater, 37212
        • Ikke rekrutterer endnu
        • VA Tennessee Valley Healthcare System
        • Ledende efterforsker:
          • John Curci, MD
        • Kontakt:
    • Texas
      • Houston, Texas, Forenede Stater, 77004
      • Plano, Texas, Forenede Stater, 75093
        • Rekruttering
        • Baylor Scott & White Medical Center
        • Ledende efterforsker:
          • William Shutze, MD
        • Kontakt:
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84132
        • Rekruttering
        • University of Utah Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Cali Johnson, MD
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
        • Rekruttering
        • Inova Fairfax Medical Campus Inova Health Systems
        • Kontakt:
        • Ledende efterforsker:
          • Kendal Endicott, MD
      • Norfolk, Virginia, Forenede Stater, 23507
        • Rekruttering
        • Sentara Health
        • Ledende efterforsker:
          • David Dexter, MD
        • Kontakt:
    • Washington
      • Seattle, Washington, Forenede Stater, 98104
        • Rekruttering
        • University of Washington at Harborview Medical Center
        • Kontakt:
        • Ledende efterforsker:
          • Benjamin Starnes, MD
    • Wisconsin
      • Green Bay, Wisconsin, Forenede Stater, 54301
      • Auckland, New Zealand, 1023
        • Rekruttering
        • Auckland City Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Andrew Holden, A/Prof

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. Males and females ≥21 to ≤85 years of age. Females must be of non-childbearing potential (menopause or sterilization).
  2. Subject understands the purpose of the trial, agrees to voluntarily participate in the trial, signs the informed consent and is willing to complete the follow-up according to the requirements of the protocol.
  3. Infrarenal atherosclerotic fusiform abdominal aortic aneurysm from 3.5 cm to 5.0 cm (male) and 3.5 cm to 4.5 cm (female).
  4. Infrarenal aortic neck ≥ 15 mm in length and ≤ 29 mm in diameter.
  5. Overall AAA treatment length (distal renal to distal inferior margin of the aneurysm) not to exceed 130 mm.
  6. Iliac and femoral artery access, vessel size and morphology allow endovascular access of 14F (or larger) introducer sheaths and catheters.
  7. Subject meets American Society of Anesthesiology (ASA) grade 1 through 3 criteria, inclusive.
  8. Subject has > three-year life expectancy.
  9. Subject is able and willing to comply with all required follow-up clinic visits including CT scans (pre-randomization, 6, 12, 18, 24 months and annually up to 5 years) and blood draws.

Exclusion Criteria:

  1. Subject has an acutely ruptured, leaking, dissecting or emergent aneurysm.
  2. Subject has a symptomatic infrarenal abdominal aortic aneurysm.
  3. Subject has a mycotic or infected aneurysm.
  4. Subject has current vascular injury due to trauma.
  5. Subject's aneurysm is thoracic, suprarenal or juxtarenal.
  6. Previous surgical or endovascular aneurysm repair for abdominal aortic aneurysm.
  7. Subject has anatomy of diffuse, ulcerated, or extensive (shaggy) thrombus in the neck of the AAA, that in the opinion of the vascular surgeon/investigator, could result in embolization of the thrombus.
  8. Subject has anatomy of calcification, and/or plaque within the ilio-femoral arteries or severe infrarenal neck angulation that may compromise or does not allow delivery of the Introducer Sheath or the delivery catheter of the Nectero EAST System.
  9. Subject has had a myocardial infarction within six (6) months prior to enrollment or elevated CK enzymes or troponin indicative of an evolving MI prior to procedure.
  10. Subject has current angina, unstable angina, or other active cardiac condition such as congestive heart failure III and IV, atrial arrhythmia, ventricular arrhythmia, or valvular disease, requiring intervention.
  11. Subject has undergone other major surgery within the 30 days prior to enrollment.
  12. Subjects with any transient ischemic attack (TIA) or ischemic stroke within 3 months.
  13. Known allergy to contrast material that cannot be adequately premedicated, delivery system materials (i.e., nylon, polyurethane) and/or pentagalloylglucose (PGG).
  14. Subject is morbidly obese or has other clinical conditions that severely inhibit X-ray visualization of the aorta.
  15. Subject has connective tissue/collagen disorder (e.g., Marfan syndrome, vascular Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome, Eaton Syndrome, Bessel-Hagen disease, etc.).
  16. Known contraindication to undergoing angiography or receiving systemic anticoagulation during the procedure.
  17. Subject has active systemic infection.
  18. Subject is participating in another research trial that could interfere with the results of the trial (e.g., drug trial).
  19. Subject has other medical, social, or psychological problems that, in the opinion of the investigator, preclude them from participation in the trial and to undergo the procedures and evaluations pre- and post-treatment.
  20. Subject has dialysis dependent renal failure or baseline serum creatinine level >2.5mg/dL or eGFR < 45 mL/min/1.73m2.
  21. Subjects with aminotransferase (ALT and/or AST) which is ≥1.5x upper limit of normal (ULN) or TB that is our of normal range for the evaluating laboratory.
  22. Subjects that may not tolerate the lowering of their systolic blood pressure to approximately 100mmHg, should not be considered for this study or treated using the Nectero EAST System.
  23. Subjects that may not be able to tolerate transient occlusion of the aorta should not be considered for this study.
  24. Subjects with saccular AAA.
  25. Subjects with rapidly expanding AAA (previous diameter increases of ≥0.5 cm in 6-months or ≥1 cm in 1 year) as these should be evaluated for immediate repair.
  26. Subjects who are not suitable for the Nectero EAST System treatment, as determined by the investigator.
  27. Subjects with INR out of normal range for the evaluating laboratory for a subject not on anti-coagulant therapy; or INR >3 for a subject on anti-coagulant therapy.
  28. Subjects with active/acute or a history of unstable chronic liver disease or current liver disease including but not limited to liver transplant, known genetic disorders such as Gilbert syndrome or other liver diseases.
  29. Subjects with cirrhosis (e.g., known history or new clinical diagnosis by elastography with a fibrosis score of F3 or F4 and/or steatosis grade of S3).
  30. Subjects with uncontrolled alcohol use disorder or current alcohol use putting them at risk of liver disease: including consumption of above one standard drink per day for women and two standard drinks per day for men.
  31. Subjects with known right-sided heart failure or pathologically dilated inferior vena cava or hepatic veins indicative of congestive hepatopathy.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Treatment Arm

Participants assigned to the treatment arm will undergo an endovascular procedure using the Nectero EAST System to deliver the Stabilizer Infusion Solution directly inside the aneurysm. This is a one-time local delivery of the product. Following treatment, surveillance of their AAA will be conducted using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years.

Intervention: Drug: Stabilizer

Treated subjects will undergo an endovascular procedure with the Nectero EAST system and receive the Stabilizer Infusion Solution (drug) within 30 days of the study eligibility by CT scan as a one-time local delivery of the drug.

Ingen indgriben: Control Arm

Participants assigned to the control arm will undergo surveillance of their AAA using CT scans at 6 months, 12 months, 18 months, 24 months, and annually for 5 years.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Primary Endpoint
Tidsramme: 24 months

The primary endpoint is the composite of all AAA-related death, rupture and repair (open-surgical, EVAR, or clinically indicated for repair as adjudicated by a committee of clinical experts blinded to the assigned arm).

24 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Growth
Tidsramme: 24 months

The growth over time in aneurysm diameter based on CT core laboratory readings.

24 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Daniel Clair, MD, Vanderbilt University Medical Center
  • Ledende efterforsker: Grace Wang, MD, University of Pennsylvania

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

25. oktober 2023

Primær færdiggørelse (Anslået)

30. juni 2028

Studieafslutning (Anslået)

31. december 2032

Datoer for studieregistrering

Først indsendt

7. august 2023

Først indsendt, der opfyldte QC-kriterier

14. august 2023

Først opslået (Faktiske)

21. august 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

28. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

23. september 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • EAST002

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner